Myelodysplastic Syndrome Epidemiology Forecast Insight

DelveInsight’s ‘Myelodysplastic Syndrome (MDS) - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the MDS, historical and forecasted epidemiology as well as the MDS market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Myelodysplastic Syndrome Disease Understanding

Myelodysplastic Syndrome Overview

Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow. In MDS, also known as myelodysplasia, the bone marrow cells do not develop into mature blood cells; instead, these cells stay within the bone marrow in an immature state. There are many subtypes of MDS; some cases are mild, while others are more severe and carry a high risk of becoming acute myelogenous leukemia (AML). The subtype and the severity case depend on many factors, including how low the blood counts are and any genetic changes in bone marrow cells. MDS and aplastic anemia (AA) and Paroxysmal nocturnal hemoglobinuria (PNH), are bone marrow failure diseases. Bone marrow failure occurs when the marrow does not produce enough red cells, white cells, or platelets, or the produced blood cells are damaged or defective. This means the body cannot supply itself with the blood it needs.

 

MDS may be de novo or related to prior use of chemotherapeutic agents, also known as treatment-related MDS (t-MDS). The actual preceding factor(s) for de novo MDS is not entirely understood but assumed to occur from an oncogenic process resulting in one or more somatic mutations. Over recent years, much insight has been gained into mutations that are commonly altered in MDS due to advances and the rapid availability of gene sequencing. With these developments, researchers can identify one or more driver mutations in up to 80─90% of patients with some of the most common ones, including SF3B1, TET2, SRSF2, ASXL1, DNMT3A, RUNX1, U2AF1, TP53, and EZH2. RUNX1, for example, is a mutation noted to disrupt normal hematopoiesis. More than 100 genes are recurrently mutated in MDS, and these encode spliceosome components, chromatin remodeling factors, epigenetic pattern modulators, and transcription factors, among others.

Myelodysplastic Syndrome Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of MDS, Age-specific Incident Population of MDS, Subtype-specific Incident Population of MDS, Risk-specific Incident Population of MDS, and Mutation-specific Incident Population of MDS in the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.

 

Key Findings

This section provides glimpse of the MDS epidemiology in the 7MM.

  • In 2020, the incident population of MDS in the 7MM was 41,586.
  • Epidemiology assessed for MDS showed that the US, in 2020, accounted for approximately 20,428 incident cases of MDS.
  • In the United States, in 2020, there were 240, 1,070, 3,654, 7,283 and 8,181 cases, in the age groups 0–49 years, 50–59 years, 60–69 years, 70–79 years, and 80+ years, respectively.
  • As per the estimates, in the United States, there were 6,741, 1,021, 2,043, 6,333, 3,064, and 1,226 cases of RAEB/MDS-EB, del(5q) MDS, MDS-RS/RARS, MDS-MLD/RCMD, MDS-SLD/RCUD, and MDS-U subtypes in 2020, respectively.
  • In 2020, there were 4,903, 2,043, 817, 2,043, 2,554, 1,839, 4,086, 2,860, 817, and 1,021 cases, for the mutation SF3B1, SRSF2, U2AF1, DNMT3A, RUNX1 TP53, TET2, ASXL1, ZRSR2, and IDH2 respectively, in the US.
  • In the US, based on the IPSS scoring, Low-risk MDS and High-risk MDS accounted for the highest and lowest cases, respectively, in 2020. On the other hand, based on the IPSS-R scoring, Low-risk MDS and Very high-risk MDS accounted for the highest and lowest cases, respectively, in 2020.
  • Among the EU-5 countries in 2020, Germany had the highest incident population of MDS patients with 4,515 cases, followed by France (4,371) and UK (3,302). In contrast, Spain had the lowest cases (2,010) in 2020.
  • As per the estimates, Japan accounted for 3,909 incident MDS cases in 2020.

Country Wise- Myelodysplastic Syndrome Epidemiology

The epidemiology segment also provides the Myelodysplastic Syndrome epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Scope of the Report

  • The report covers the descriptive overview of Myelodysplastic Syndrome, explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Myelodysplastic Syndrome.

Report Highlight

  • Ten Year Forecast of Myelodysplastic Syndrome
  • 7MM Coverage
  • Delvelnsight has analysed incident population of Myelodysplastic Syndrome in the 7MM which suggests that the patient pool will increase during the forecast period of 2021–2030.
  • Age-specific data of MDS suggests that incidence of MDS in the US, was highest in the age group of 80+ years, followed by 70–79 years and 60–69 years.
  • The scope of the report also encompasses another major segment, i.e., mutation-specific incidence MDS, wherein the number of patients suffering from mutations of  SF3B1, SRSF2, U2AF1, DNMT3A, RUNX1 TP53, TET2, ASXL1, ZRSR2, and IDH2 were calculated.
  • There are sub- types of MDS considered in this report include MDS can be broadly categorized into the following subtypes: RAEB/MDS-EB, del(5q) MDS, MDS-RS/RARS, MDS-MLD/RCMD, MDS-SLD/RCUD, and MDS-U.

Analyst Comments

  • The incident rates differ slightly in the 7MM countries, with the highest incidence observed in the US and the least in Japan.
  • The incidence rates differ vastly among different age groups, with low incidence observed in the younger population (1–3 per 100,000 people per year) compared to the older population (20–30 per 100,000 people per year).
  • However, MDS patients are slightly younger in the age in Japan as compared to the patients in western countries.
  • In countries such as Germany and Japan, where ageing population declines during the forecast year, we have assumed a minimal increase in growth of MDS cases.

Key Questions Answered

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Myelodysplastic Syndrome?
  • What is the historical Myelodysplastic Syndrome patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Myelodysplastic Syndrome in the 7MM?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Myelodysplastic Syndrome?
  • Out of the above-mentioned countries, which country would have the highest incident population of Myelodysplastic Syndrome during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Myelodysplastic Syndrome report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Myelodysplastic Syndrome market.
  • Quantify patient share distribution in the 7MM for Myelodysplastic Syndrome.
  • The Myelodysplastic Syndrome epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Myelodysplastic Syndrome epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the Ten-year forecast period using reputable sources.

1. Key Insights

2. Report Introduction

3. Myelodysplastic Syndrome (MDS) Market Overview at a Glance

4. Disease Background and Overview

4.1. Introduction

4.2. Classification

4.2.1. WHO Classification System (2016)

4.2.2. French American British (FAB) Classification System

4.3. Sign and Symptoms

4.3.1. Low Red Blood Cell Counts

4.3.2. Low White Blood

4.3.3. Low Platelet Count

4.4. Causes and Risk factors

4.5. Prevention

4.6. Clinical Presentation

4.7. Risk Stratification

4.7.1. International Prognostic Scoring System (IPSS)

4.7.2. Revised International Prognostic Scoring System (IPSS-R)

4.8. Pathophysiology

4.8.1. Haploinsufficiency through Chromosomal Deletion

4.8.2. Recurrently Mutated Genes

4.8.3. Pre-MDS Clonal Mutations

4.8.4. Post-MDS Clonal Mutations

4.8.5. Epigenetic Changes

4.8.6. Ineffective Hematopoiesis

4.8.7. Microenvironment and Immune Cells

4.9. Prognosis

4.10. Mutations

4.11. Differential Diagnosis

4.12. Diagnosis

4.12.1. History and Physical Examination

4.12.2. Blood Examination

4.12.3. Bone Marrow Examination

4.12.4. Cytochemistry and Immunocytochemistry

4.12.5. Cytogenetic and molecular features

5. Diagnostic Algorithm

6. British Society for Hematology guidelines for the Diagnosis and Evaluation of Prognosis of Adult MDS (2021)

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Epidemiology Methodology

7.3. Total Incident Population of Myelodysplastic Syndrome (MDS) in the 7MM

7.4. Epidemiology of Myelodysplastic Syndrome (MDS)

7.4.1. US

7.4.2. EU-5

7.4.3. Japan

7.5. The United States

7.5.1. Total Incident Population of Myelodysplastic Syndrome (MDS) in the United States

7.5.2. Age-specific Incident Population of Myelodysplastic Syndrome (MDS) in the United States

7.5.3. Subtype-specific Incident Population of Myelodysplastic Syndrome (MDS) in the United States

7.5.4. Risk-specific incident population of Myelodysplastic Syndrome (MDS) in the United States

7.5.5. Mutation-specific incident population of Myelodysplastic Syndrome (MDS) in the United States

7.6. EU5

7.6.1. Total Incident Population of Myelodysplastic Syndrome (MDS) in EU-5

7.6.2. Age-specific Incident Population of Myelodysplastic syndrome (MDS) in EU-5

7.6.3. Subtype-specific Incident Population of Myelodysplastic syndrome (MDS) in EU-5

7.6.4. Risk-specific incident population of Myelodysplastic syndrome (MDS) in EU5

7.6.5. Mutation-specific incident population of Myelodysplastic syndrome (MDS) in EU5

7.7. Japan

7.7.1. Total Incident Population of Myelodysplastic Syndrome (MDS) in Japan

7.7.2. Age-specific Incident Population of Myelodysplastic Syndrome (MDS) in Japan

7.7.3. Subtype-specific Incident Population of Myelodysplastic Syndrome (MDS) in Japan

7.7.4. Risk-specific incident population of Myelodysplastic syndrome (MDS) in Japan

7.7.5. Mutation-specific incident population of Myelodysplastic syndrome (MDS) in Japan

8. Organizations contributing towards Myelodysplastic Syndrome (MDS)

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of Myelodysplastic Syndrome (MDS) Market, and Epidemiology (2018–2030)

Table 2: Key Events

Table 3: Total Incident Population of MDS in the 7MM (2018–2030)

Table 4: Total Incident Population of MDS in the US (2018–2030)

Table 5: Age-specific Incident Population of MDS in the United States (2018–2030)

Table 6: Subtype-specific Incident Population of MDS in the US (2018–2030)

Table 7: Risk-specific incident population of MDS in the United States (2018–2030)

Table 8: Mutation-specific incident population of MDS in the United States (2018–2030)

Table 9: Total Incidence of MDS in EU-5 (2018–2030)

Table 10: Age-specific Incident Population of MDS in EU-5 (2018–2030)

Table 11: Subtype-specific Incident Population of MDS in EU-5 (2018–2030)

Table 12: Risk-specific incident population of MDS in EU5 (2018–2030)

Table 13: Mutation-specific incident population of MDS in EU5 (2018–2030)

Table 14: Total Incident Population of MDS in Japan (2018–2030)

Table 15: Age-specific Incident Population of MDS in Japan (2018–2030)

Table 16: Subtype-specific Incident Population of MDS in Japan (2018–2030)

Table 17: Risk-specific incident population of MDS in Japan (2018–2030)

Table 18: Mutation-specific incident population of MDS in Japan (2018–2030)

Table 19: Organizations Contributing Toward the Fight Against Myelodysplastic Syndrome

Table 20: Reblozyl, Clinical Trial Description, 2021

Table 21: Inqovi, Clinical Trial Description, 2021

Table 22: Comparison of emerging drugs under development

Table 23: Comparison of emerging drugs under development

Table 24: Roxadustat (FG-4592), Clinical Trial Description, 2021

Table 25: Venclexta (Venetoclax) + Azacitidine, Clinical Trial Description, 2021

Table 26: Magrolimab ± Azacitidine, Clinical Trial Description, 2021

Table 27: Sabatolimab (MBG453) + Azacitidine), Clinical Trial Description, 2021

Table 28: SY-1425 + Azacitidine, Clinical Trial Description, 2021

Table 29: Pevonedistat + Azacitidine, Clinical Trial Description, 2021

Table 30: Glasdegib + Azacitidine, Clinical Trial Description, 2021

Table 31: Imetelstat, Clinical Trial Description, 2021

Table 32: Eltanexor, Clinical Trial Description, 2021

Table 33: Bemcentinib, Clinical Trial Description, 2021

Table 34: Enasidenib, Clinical Trial Description, 2021

Table 35: CPX-351, Clinical Trial Description, 2021

Table 36: APR-246 + Azacitidine, Clinical Trial Description, 2021

Table 37: Fludarabine + Busulfan ± Clofarabine, Clinical Trial Description, 2021

Table 38: Treosulfan ± fludarabine, Clinical Trial Description, 2021

Table 39: Market Size of MDS in the 7MM in USD Million (2018–2030)

Table 40: Market Size of MDS by First Line therapies in the 7MM, in USD Million (2018–2030)

Table 41: Market Size of MDS by Second Line therapies in the 7MM, in USD Million (2018–2030)

Table 42: Key Market Forecast Assumptions for FG-4592 (Roxadustat) (for 1LOT)

Table 43: Key Market Forecast Assumptions for Venclexta ± Azacitidine (for 1LOT)

Table 44: Key Market Forecast Assumptions for Magrolimab +Azacitidine (for 1LOT)

Table 45: Key Market Forecast Assumptions for Pevonedistat ± Azacitidine (for 1LOT)

Table 46: Key Market Forecast Assumptions for SY-1425 + Azacitidine (for 1LOT)

Table 47: Key Market Forecast Assumptions for Glasdegib + Azacitidine (for 1LOT)

Table 48: Key Market Forecast Assumptions for Imetelstat (for 2LOT)

Table 49: Key Market Forecast Assumptions for Bemcentinib (for 2LOT)

Table 50: Key Market Forecast Assumptions for Eltanexor (ATG 016/KPT-8602) (for 2LOT)

Table 51: Key Market Forecast Assumptions for Enasidenib + Azacitidine (for 2LOT)

Table 52: Key Market Forecast Assumptions for CPX-351 (for 2LOT)

Table 53: Key Market Forecast Assumptions for Eprenetapopt

Table 54: Market Size of MDS in the US, USD Million (2018–2030)

Table 55: Market Size of MDS by First Line therapies in the US, USD Million (2018–2030)

Table 56: Market Size of MDS by therapies in the US, USD Million (2018–2030)

Table 57: EU5 Market Size of MDS in USD Million (2018–2030)

Table 58: Market Size of MDS by First Line Therapies in EU5, USD Million (2018–2030)

Table 59: EU5 Market Size of MDS by Second Line Therapies in USD Million (2018–2030)

Table 60: Japan Market Size of MDS in Japan, USD Million (2018–2030)

Table 61: Market Size of MDS by First Line Therapies in Japan, USD Million (2018–2030)

Table 62: Market Size of MDS by Second Line Therapies in Japan, USD Million (2018–2030)

List of Figures

Figure 1: Total Incident Population of MDS in the 7MM (2018–2030)

Figure 2: Total Incident Population of MDS in the US (2018–2030)

Figure 3: Age-specific Incident Population of MDS in the United States (2018–2030)

Figure 4: Subtype-specific Incident Population of MDS in the US (2018–2030)

Figure 6: IPSS-R Risk-specific incident population of MDS in the United States (2018–2030)

Figure 5: IPSS Risk-specific incident population of MDS in the United States (2018–2030)

Figure 7: Mutation-specific incident population of MDS in the United States (2018–2030)

Figure 8: Total Incident Population of MDS in EU5 (2018–2030)

Figure 9: Age-specific Incident Population of MDS in EU-5 (2018–2030)

Figure 10: Subtype-specific Incident Population of MDS in EU-5 (2018–2030)

Figure 11: IPSS-R Risk-specific incident population of MDS in EU5 (2018–2030)

Figure 12: IPSS Risk-specific incident population of MDS in EU5 (2018–2030)

Figure 13: Mutation-specific incident population of MDS in EU-5 (2018–2030)

Figure 14: Total Incident Population of MDS in Japan (2018–2030)

Figure 15: Age-specific Incident Population of MDS in Japan (2018–2030)

Figure 16: Subtype-specific Incident Population of MDS in Japan (2018–2030)

Figure 17: IPSS-R Risk-specific incident population of MDS in Japan (2018–2030)

Figure 18: IPSS Risk-specific incident population of MDS in Japan (2018–2030)

Figure 19: Mutation-specific incident population of MDS in Japan (2018–2030)

Figure 20: Market Size of MDS in the 7MM in USD Million (2018–2030)

Figure 21: Market Size of MDS by First Line Therapies in the 7MM, in USD Million (2018–2030)

Figure 22: Market Size of MDS by Second Line Therapies in the 7MM, in USD Million (2018–2030)

Figure 22: Market Size of MDS in the US, USD Millions (2018–2030)

Figure 23: Market Size of MDS by First Line therapies in the US, USD Million (2018–2030)

Figure 24: Market Size of MDS by therapies in the US, USD Million (2018–2030)

Figure 25: Market Size of MDS in EU5, USD Million (2018–2030)

Figure 26: EU5 Market Size of MDS by First Line Therapies in USD Million (2018–2030)

Figure 27: EU5 Market Size of MDS by Second Line Therapies in USD Million (2018–2030)

Figure 28: Market Size of MDS in Japan, USD Million (2018–2030)

Figure 29: Japan Market Size of MDS by First Line Therapies, USD Million (2018–2030)

Figure 30: Japan Market Size of MDS by Second Line Therapies, USD Million (2018–2030)

Forward to Friend

Need A Quote